ASCO 2023 | Advancements in systemic therapy for kidney cancer: implications for treatment decision-making

Shawn Dason, MD, The Ohio State University Comprehensive Cancer Center, Columbus, OH, highlights the significant advancements in systemic therapy for kidney cancer in recent years, leading to improved outcomes compared to the past. While surgical approaches like nephrectomy and metastasectomy haven’t seen major breakthroughs, it’s essential to recognize the changing landscape and consider the latest data when making treatment decisions. Late-breaking abstracts of Phase III trials have shown promising long-term efficacy with systemic therapies. Dr Dason emphasizes the incorporation of the evolving knowledge of systemic treatments into the overall management of kidney cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.